Trialbee, a Swedish developer of software for use in clinical trials, has appointed Ulf Wiinberg, formerly Chief Executive of H. Lundbeck, as Chairman of the Board.
Lars Birgerson, who was recently Senior Vice President, Medical R&D at Bristol-Myers Squibb, has also become a member of the board.
These appointments bring a wealth of expertise from the life science industry and medical world to the firm as it prepares to expand into new market segments.
Wiinberg brings 30 years of experience from the pharmaceutical industry to the company.
He said Trialbee's mission to digitise the clinical trial process 'has the potential to transform the pharmaceutical industry'.
'With my background I clearly see the value Trialbee can bring. I decided to join the board to be part of the journey from start-up to global brand.'
Birgerson brings extensive knowledge of drug development, medical affairs, health economics and outcomes research.
'Trialbee's solution provides a great opportunity to connect patients and clinical research,' he said.
'Empowering patients is key to secure successful outcomes in the digital era. I'm honoured to bring my expertise and international network to help facilitate this transformation, improving the development of new and better treatments to help patients.'